Does Rivaroxaban Better than Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing PCI?
<p>ACS: Acute Coronary Syndrome; AF: Atrial Fibrillation; DAPT: Dual Antiplatelet Therapy; INR: InternationalNormalized Ratio; MI: Myocardial Infarction; PCI: Percutaneous Coronary Intervention; PIONEER AF-PCI: Open-Label, Randomized, Controlled, Multicenterstudy Exploring two Treatment Strate...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Archives of Hematology Case Reports and Reviews - Peertechz Publications,
2016-12-30.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | peertech__10_17352_ahcrr_000003 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Maamar Kara |e author |
| 700 | 1 | 0 | |a Omar Aitmokhtar |e author |
| 700 | 1 | 0 | |a Adel Azaza |e author |
| 700 | 1 | 0 | |a Saber Seddiki |e author |
| 700 | 1 | 0 | |a Faiza Harbi |e author |
| 700 | 1 | 0 | |a Arezki Sik |e author |
| 700 | 1 | 0 | |a Kheireddine Merad |e author |
| 700 | 1 | 0 | |a Salim Benkhedda |e author |
| 245 | 0 | 0 | |a Does Rivaroxaban Better than Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing PCI? |
| 260 | |b Archives of Hematology Case Reports and Reviews - Peertechz Publications, |c 2016-12-30. | ||
| 520 | |a <p>ACS: Acute Coronary Syndrome; AF: Atrial Fibrillation; DAPT: Dual Antiplatelet Therapy; INR: InternationalNormalized Ratio; MI: Myocardial Infarction; PCI: Percutaneous Coronary Intervention; PIONEER AF-PCI: Open-Label, Randomized, Controlled, Multicenterstudy Exploring two Treatment Strategiesof Rivaroxaban and a Dose-Adjusted Oral Vitamink Antagonist Treatment Strategy in Subjectswith Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention; TIMI: Thrombolysis In Myocardial Infarction; VKA: Vitamin K Antagonist</p><p>Approximately 15% of AF patients have a history of myocardial infarction. Between 5-15% of them will require stenting at some point in their lives with the need for a triple therapy combining an oral anticoagulant, a P2Y12 Inhibitor and aspirin [1-3]. This combination requires careful evaluation of bleeding risk, stroke risk and the risk of acute coronary syndromes (ACS) to reduce the risk of major hemorrhage [4-6]. In this context, the PIONEER AF-PCI [7], trial was conducted to evaluate the effectiveness and safety of anticoagulation with rivaroxaban plus either one or two antiplatelet agents.<br></p> | ||
| 540 | |a Copyright © Maamar Kara et al. | ||
| 546 | |a en | ||
| 655 | 7 | |a Editorial |2 local | |
| 856 | 4 | 1 | |u https://doi.org/10.17352/ahcrr.000003 |z Connect to this object online. |